Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I read MedCity because it captures the pulse of what's going on in healthcare innovation, a go to source. I also like how MedCity supports women in digital health.”

Dr. Charlene Ngamwajasat, @doctorcharlene, Physician and techie


Sign up for our daily newsletter


New follistatin gene therapy for muscular dystrophy gets orphan drug status

8:35 am by | 0 Comments

An experimental drug being developed by Milo Biotechnology for the treatment of certain neuromuscular diseases has been given orphan drug designation by the U.S. Food and Drug Administration.

The Cleveland company’s drug candidate, AAV1-FS344, is a gene delivery therapy that’s designed to produce follistatin, a protein associated with muscle size and strength, in patients with Becker and Duchenne muscular dystrophy.

BMD and DMD are similar forms of muscular dystrophy caused by a gene mutation that results in either no or only partial production of the protein dystrophin. Patients with these conditions experience muscle weakness, cardiac complications and respiratory complications that progress over time.

Advertisement

Milo Biotechnology’s drug is based on technology licensed from Nationwide Children’s Hospital in Columbus, where a Phase 1/2 clinical trial is underway in adult patients with BMD and inclusion body myositis.

It’s not the only muscular dystrophy drug in clinical trials. An experimental drug from Sarepta Therapeutics has gotten some attention this year as a small clinical trial produced promising results of improved muscle function in boys with muscular dystrophy. Researchers at Cedars-Sinai Medical Center are also testing the erectile dysfunction drug Cialis, marketed by Eli Lilly & Co., in BMD patients. Last month, researchers reported that it corrected abnormal blood flow in patients with the condition.

With the orphan drug designation, Milo becomes qualified for a tax credit and seven years of marketing exclusivity. The company, which received a $250,000 investment from economic development group JumpStart earlier this year (Disclosure: JumpStart is also an investor in MedCity Media), is led by former BioEnterprise Entrepreneur-in-Residence Al Hawkins.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Deanna Pogorelc

By Deanna Pogorelc MedCity News

Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what’s next in healthcare. She has a bachelor’s degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.
More posts by Author

0 comments